Opinion statement
-
Prevention of gastrointestinal toxicity begins with the selection of an appropriate analgesic or anti-inflammatory agent. For conditions without inflammation, such as some cases of osteoarthritis, an analgesic with no risk for gastrointestinal toxicity is appropriate.
-
Risk factors for nonsteroidal anti-inflammatory drug (NSAID)-related complications include advanced age; history of ulcer disease or gastrointestinal bleeding; concomitant corticosteroid or anticoagulant use; use of high-dose or multiple NSAIDs; and certain chronic diseases, such as cardiovascular disease. If an NSAID must be used in a patient with risk factors, the patient should receive the lowest-risk NSAID and, in most cases, co-therapy to reduce the risk for NSAID-associated ulcers and their complications.
-
The PGE1 prostaglandin analogue misoprostol is highly efficacious for the prevention of both gastric and duodenal ulcers and has also been shown to reduce the incidence of NSAID-induced ulcer complications. Side effects, such as diarrhea, may limit patient acceptance of the drug.
-
Acid suppression with traditional ulcer-healing doses of H2-blockers significantly reduces rates of duodenal ulcer but is ineffective in reducing gastric ulceration. More potent acid inhibition with double-dose H2-blockers reduces rates of both gastric and duodenal ulcers.
-
Proton-pump inhibitors, such as omeprazole, have been shown to prevent gastric and duodenal ulcers with an efficacy equal to that of misoprostol. They also reduce NSAID-related dyspepsia.
-
Specific cyclooxygenase-2 (COX-2) inhibitors are associated with a markedly reduced rate of endoscopic ulcers. Very high-risk patients who receive these agents may still require co-therapy to prevent complications or reduce dyspepsia. This protocol may be changed by the results of long-term gastrointestinal outcome studies now underway.
Similar content being viewed by others
References and Recommended Reading
Stat Bull Metrop Insur Co. Antiarthritis medication usage, United States, 1991. 1992, 73:25–34.
Singh G, Ramey DR: NSAID-induced gastrointestinal complications: the ARAMIS perspective-1997. J Rheumatol 1998, 25:16.
Goldstein JL: Public misunderstanding of nonsteroidal antiinflammatory drug (NSAID)-mediated gastrointestinal complications toxicity: a serious potential health threat. Gastroenterology 1998, 114:G0555.
Scheiman JM: NSAIDs, cytoprotection, and gastrointestinal injury. Gastroenterol Clin North Am 1996, 25:279–298.
Vane JR, Mitchell JA, Appelton I, et al.: Inducible isoforms of cyclooxygenase and nitric acid synthase in inflammation. Proc Natl Acad Sci U S A 1994, 91:2046–2050.
Cryer B, Feldman M: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal antiinflammatory drugs. Am J Med 1998, 104:413–421. This paper highlights the difficulties in characterizing NSAIDs selectively for COX isoenzymes.
Scheiman JM, Elta GH: Gastroduodenal mucosal damage with salsalate versus aspirin: results of experimental models and endoscopic studies in humans. Semin Arthritis Rheum 1990, 20:121–127.
Roth SH, Tindall EA, Jain AD, et al.: A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal mucosa. Arch Intern Med 1993, 153:2565–2571.
Laine L, Sloane R, Ferretti M, Cominelli F: A randomized, double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc 1995, 42:428–433.
Slattery J, Warlow CP, Shorrock CJ, Langman MJS: Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin-analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995, 37:509–511.
Kurata JH, Abbey DE: The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol 1990, 12:260–266.
Weil J, Colin-Jones D, Langman M, et al.: Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995, 310:827–830.
Cryer B, Luk G, Feldman M: Effects of very low doses of aspirin (ASA) on gastric duodenal and rectal prostaglandins (PG2) and mucosal injury. Gastroenterology 1995, 108:A77.
Silverstein F, Graham D, Senior J, et al.: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123:241–249.
Henry D, Lim L, Garcia Rodriguez L, et al.: Variability in risk of gastrointestinal complications with individual NSAIDs: results of a collaborative meta-analysis. BMJ 1996, 312:1563–1566. This provides an important synthesis of data on the relative ulcerogenicity of various NSAIDs.
Armstrong CP, Blower AL: Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987, 28:527–532.
Hawkey CJ, Langstrom G, Naesdal J, Yeomans N: Significance of symptoms during healing and maintenance of NSAID-associated gastroduodenal lesions with omeprazole, misoprostol, and ranitidine. Gastroenterology 1997, 112:A144.
Roth SH: Efficacy of antacid therapy for NSAIDinduced symptomatic gastropathy. Am J Gastroenterol 1993, 88:1516.
Bijlsma JW: Treatment of endoscopy-negative NSAIDinduced upper gastrointestinal symptoms with cimetidine: an international multicentre collaborative study. Aliment Pharmacol Ther 1988, 2(suppl 2):75–84.
Ekstrom P, Carling L, Wetterhus S, et al.: Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. Scand J Gastroenterol 1996, 31:753–758.
Graham D, Agrawal N, Roth S: Prevention of NSAIDinduced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988, 2:1277–1280.
Raskin JB, White R, Jaszewski R, et al.: Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double blind, multicenter study. Am J Gastroenterol 1996, 91:223–227.
Raskin JB, White RH, Jackson JE: Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995, 123:344–350.
Taha AS, Hudson N, Hawkey CJ, et al.: Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Engl J Med 1996, 334:1435–1439.
Cullen D, Bardhan KD, Eisner M, et al.: Primary gastroduodenal prophylaxis with omeprazole for NSAID users. Aliment Pharmacol Ther 1998, 12:135–140.
Yeomans ND, Zsolt T, Juhasz L, et al.: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998, 338:719–726.
Hawkey CJ, Karrasch JA, Szczepanski L, et al.: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998, 338:727–734. This paper supports the use of proton-pump inhibitors as an alternative to misoprostol for NSAID prophylaxis.
Kurumbail RG, Stevens AM, Gierse JK, et al.: Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996, 384:644–648.
Hawkey CJ: COX-2 inhibitors. Lancet 1999, 353:307–314. This is a timely, comprehensive review.
Hawkey C, Laine L, Simon T, et al.: A comparison of the effect of rofecoxib (a COX-2 specific inhibitor), ibuprofen, or placebo on the gastroduodenal mucosa of osteoarthritics. In press.
Scheiman JM: Commentary on “Meta analysis: Misoprostol reduced NSAID-induced gastrointestinal injury.” ACP J Club 1997, 124:34.
Simon LS, Hatoum HT, Bittman RM, et al.: Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA Trial. Fam Med 1996, 28:204–210.
Quang-Hiang J, Hunt R: Gastrointestinal complications associated with nabumetone. Am J Med 1999, In press.
Fendrick AM, Bandekar R, Chernew ME, Scheiman JM: Impact of NSAID choice and patient symptoms on the cost-effectiveness of strategies to prevent NSAID gastropathy. Gastroenterology 1998, 114:A120.
Schoenfeld P: Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med 1999, In press.
Elliott SN, McKnight W, Cirino G, Wallace JL: A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 1995, 109:524–533.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scheiman, J.M. Preventing NSAID toxicity to the upper gastrointestinal tract. Curr Treat Options Gastro 2, 205–213 (1999). https://doi.org/10.1007/s11938-999-0060-z
Issue Date:
DOI: https://doi.org/10.1007/s11938-999-0060-z